This content is only available within our institutional offering.

03 Feb 2025
UCB - Recent Rystiggo and Bimzelx updates to bolster sales potential

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
UCB - Recent Rystiggo and Bimzelx updates to bolster sales potential
Last Friday, UCB announced that the CHMP has issued a positive opinion for the self-admin option of Rystiggo via infusion (syringe pump) or a new manual push syringe method. These new admin strategies provide patient optionality and add additional administration convenience which we expect the younger gMG patient population to benefit from especially. As a result thereof, we revised our sales estimates upwards with our 2030 sales now amounting to close to EUR 850m (+17% vs. VA CSS). While the JPN dossier is in review, IR indicated that a U.S. approval is “not for the near term”.Remember that ARGX's Hytrulo